Skip to main content
Caplight Logo









Provigate, Inc.

Provigate, Inc.

Private
TokyoHealthcare & Life Scienceshttps://provigate.com/en/

Last Round

Grant

Oct 28, 2024

Total Funding Raised

$13.33M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Provigate, Inc. is a healthcare technology company that develops non-invasive blood glucose monitoring sensors, devices, and digital health applications to support diabetes prevention and management.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT, Sensors, Patient Engagement

Business Model

B2B

Customer Profile

Services & Consulting, Hardware + Subscription

AI Layer

Application

Keywords

glucose monitoringglycated albuminGAdiabetes managementcgmdigital healthremote patient monitoringRPMbiosensorhealth techbehavioral change appminimally invasivepre-diabeteshealth and productivity managementmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Provigate, Inc. Comparables

Compare Provigate, Inc. with similar companies based on industry and business-model similarity.

Provigate, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Epinex Diagnostics, Inc.
77%
Orange Biomed
66%
Roche Holding
64%

Provigate, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 28, 2024
Series BOct 28, 2024
VC RoundJan 18, 2022
StrategicJan 18, 2022
VC RoundSep 27, 2021
Grant
Jul 29, 2021

Key People

Founding team and executive leadership

Koshin Sekimizu

President and CEO

Executive Team

Provigate, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 290% MoM to 5.6K.

  • Oct 28, 2025

    Exhibiting at the 25th Annual Diabetes Technology Meeting in October 2025.

Provigate, Inc. Filings

Explore SEC and related filing metadata, where available.

Provigate, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Provigate, Inc.'s valuation, stock price, and market status.

Is Provigate, Inc. a public or private company?

Provigate, Inc. is a private company.

What is the current stock price of Provigate, Inc.?

Provigate, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Provigate, Inc. worth (valuation)?

Valuation information for Provigate, Inc. is not publicly available.

Can I buy Provigate, Inc. stock?

Provigate, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Provigate, Inc.'s last funding round?

Funding round information for Provigate, Inc. is not publicly available.

Who are the main investors in Provigate, Inc.?

Investor information for Provigate, Inc. is not publicly disclosed.

Will Provigate, Inc. IPO soon?

No public IPO plans have been announced for Provigate, Inc..

How can I track Provigate, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Provigate, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTokyo
Employee Range14
Year Founded2015
Last FundingOct 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?